Aegis Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold following mixed clinical data.Analyst Raghuram Selvaraju comments, "Earlier this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE